StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-22 | $208.98 | $208.05 | -0.45% | 1.1M |
| 05-26 | $207.63 | $207.98 | +0.17% | 1.7M |
| 05-27 | $209.07 | $206.10 | -1.42% | 1.3M |
| 05-28 | $205.59 | $203.42 | -1.06% | 1.6M |
| 05-29 | $203.75 | $190.57 | -6.47% | 3.5M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
6-factor scoring with sector-relative rank. Updated daily.
Each row shows where RMD sits in our scored universe today on a single observational measurement. P85 means RMD ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $4.19B | $2.76B | $1.34B | $5.15B |
Operating Income | $1.44B | $938.20M | $446.54M | $1.69B |
Net Income | $1.14B | $392.59M | $348.54M | $1.40B |
EPS (Diluted) | $7.79 | $5.05 | $2.37 | $9.51 |
Total Assets | $8.78B | $8.50B | $8.31B | $8.17B |
Total Liabilities | $2.29B | $2.18B | $2.19B | $2.21B |
Cash & Equivalents | $1.66B | $1.42B | $1.38B | $1.21B |
Free Cash Flow OCF − CapEx | $1.25B | $725.56M | $414.36M | $1.66B |
Shares Outstanding | 145.04M | 145.66M | 145.94M | 146.39M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.